Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.

Chondrosarcoma is a type of bone cancer that forms in the cells of cartilage. Symptoms can vary but may include swelling and pain in the area of the tumor. Surgery is usually the first treatment for ...

Bone sarcomas are rare heterogeneous tumors that affect patients of all ages including children, adolescent young adults, and older adults. They include many aggressive subtypes and patient groups ...

Chondrosarcoma is a group of bone cancers that start in the cartilage. Cartilage is a connective tissue found in many parts of your body, such as in your joints where your bones meet. About 1 in ...

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

This feature explores evolving management strategies for bone sarcomas, highlighting multidisciplinary treatment approaches ...

You may have heard about a recent first at Mayo Clinic, a total larynx transplant. What you may not have heard was what precipitated that transplant. The patient developed a rare form of cancer called ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . The patient is a 57-year-old, right-handed, retired postal worker. He presented with a chief complaint of ...

Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive outcome of the Phase II ChonDRAgon trial (NCT04950075), which found that ...